Key result
Type 1 diabetes with microvascular complications is linked to ~33% higher overall hemostatic potential versus controls.
Why the study?
The influence of thrombin activatable fibrinolysis inhibitor (TAFI) on fibrinolysis and hemostatic changes in type I diabetes mellitus patients with and without microvascular complications was unclear.
Are there differences in TAFI levels and hemostatic potential between type I diabetes patients with or without microvascular complications and healthy controls?
Population
38 patients with type I diabetes mellitus (18 with and 20 without microvascular complications) and 20 healthy controls
Comparison
Patients with microvascular complications vs patients without complications vs healthy controls
Design
Observational case-control study
Authors
Loading...
Supports prothrombotic state in complicated type 1 diabetes independent of TAFI; hypothesis-generating and requires prospective confirmation before clinical consideration.
Observational (n=58)
Are there differences in TAFI levels and hemostatic potential between type I diabetes patients with or without microvascular complications and healthy controls?
Absolute Event Rate: 8.9% vs 6.7%
p-value: p=<0.05
Patients with type I diabetes and microvascular complications exhibit an increased overall hemostatic potential indicating a prothrombotic state, which does not appear to be driven by TAFI.
Antović et al. (2003) conducted an observational in Type I diabetes mellitus (n=58). Type I diabetes mellitus with microvascular complications vs. Healthy controls was evaluated on Overall hemostatic potential (OHP) in plasma (p=<0.05). Overall hemostatic potential was significantly higher in type I diabetes patients with microvascular complications compared with healthy controls (8.9 vs 6.7; P<0.05), indicating a prothrombotic state.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: